Table of Content



COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
H. Lundbeck AS-Key Company Facts 8
H. Lundbeck AS- Company Description 9
H. Lundbeck AS- Top Executives 10
H. Lundbeck AS- Head Office & Locations 11
Head Office - Country 11
H. Lundbeck AS- Productsand Services 12
Products 12
H. Lundbeck AS- Corporate Strategy 13
H. Lundbeck AS- Business Description 19
Pharmaceutical 20
H. Lundbeck AS- ESG Spotlight 21
Environment 21
Social 22
Corporate Governance 23
H. Lundbeck AS- SWOT Analysis 24
Overview 24
Strengths 26
Weaknesses 28
Opportunities 30
Threats 33
H. Lundbeck AS- Financial Deep Dive 35
Share Price Trend - Nov-2023 to Nov-2024 (Average Share Closing Price) 35
Profit and Loss Statement 37
Summary of Profit and Loss Statement 37
Balance Sheet 39
Summary of Balance Sheet 39
Cash Flow Statement 41
Summary of Cash Flow Statement 41
Key Financial Ratio Analysis 43
H. Lundbeck AS- Ratio Charts 44
Activity Ratio Charts 44
Growth Ratios Charts 45
Leverage Ratio Charts 46
Liquidity Ratio Charts 47
Profitability Ratio Charts 48
Competing Players 49
Snapshot of Competing Players 50
Abbott Laboratories 50
Key Company Facts 50
Company Description 50
Snapshot of Competing Players 51
Eli Lilly and Company 51
Key Company Facts 51
Company Description 51
Snapshot of Competing Players 52
Novo Nordisk A/S 52
Key Company Facts 52
Company Description 52
Snapshot of Competing Players 53
Takeda Pharmaceutical Company Limited 53
Key Company Facts 53
Company Description 53
Snapshot of Competing Players 54
GlaxoSmithKline Pharmaceuticals Ltd 54
Key Company Facts 54
Company Description 54
H. Lundbeck AS - In the News 55

31-Oct-2024 -Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti (eptinezumab) in migraine prevention 55
23-Oct-2024 -Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth 56
14-Oct-2024 -Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline 56
03-Oct-2024 -Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease 57
27-Sep-2024 -Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson’s Disease and Movement Disorders 58
20-Aug-2024 -Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator 58
15-May-2024 -Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024 59
13-May-2024 -Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck 60
18-Mar-2024 -How Lundbeck used AI to qualify new drug targets for headache disorders 60
15-Mar-2024 -Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage 63
05-Mar-2024 -Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders 65
23-Feb-2024 -Lundbeck announces changes to Executive Management 67
16-Feb-2024 -Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 68
07-Feb-2024 -Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024 69
05-Feb-2024 -Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck 69

31-Jan-2024 -Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial 71
20-Dec-2023 -Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 72
H. Lundbeck AS - Key Deals 73
26-Sep-2024 - Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery 73
25-Jun-2024 - Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) 74
21-Feb-2023 - EHDEN not-for-profit and Lundbeck collaborate on first research programme, in Neuroscience 75
04-Aug-2021 - Lundbeck enters strategic research collaboration with Rgenta Therapeutics on therapies targeting RNA 76
Appendix 77
Definitions 77
SWOT Analysis 77
PESTLE Analysis 77
Value Chain Analysis 77
ESG Spotlight 77
Financial Deep Dive 77
Financial Ratios- 78
Activity Ratios 78
Growth Ratios 79
Leverage Ratios 80
Liquidity Ratios 81
Market Ratios 82
Profitability Ratios 82
Research Methodology 83
Disclaimer 84
Contact Us 84



List of Figures


Charts

Figure 1: H. Lundbeck AS- SWOT Analysis 25
Figure 2: H. Lundbeck AS-Average Share Price Trend - Nov-2023to Nov-2024 36
Figure 3: H. Lundbeck AS- Profit and Loss Statement -2020-2023 38
Figure 4: H. Lundbeck AS- Balance Sheet-2020-2023 40
Figure 5: H. Lundbeck AS- Cash Flow Statement 2020-2023 42
Figure 6: H. Lundbeck AS- Activity Ratio Charts 44
Figure 7: H. Lundbeck AS- Growth Ratio Charts (Value %) 45
Figure 8: H. Lundbeck AS- Leverage Ratio Charts 46
Figure 9: H. Lundbeck AS- Liquidity Ratio Charts 47
Figure 10: H. Lundbeck AS- Profitability Ratio Charts (Value %) 48

List of Tables


Tables
Table 1: H. Lundbeck AS - Company Facts
Table 2: H. Lundbeck AS - Digital Presence
Table 3: H. Lundbeck AS - Top Executives
Table 4: H. Lundbeck AS- Products
Table 5: H. Lundbeck AS - Share Price Trend - Nov-2023to Nov-2024
Table 6: H. Lundbeck AS - Ratio Analysis -2020-2023
Table 7: H. Lundbeck AS - Competing Players
Table 8: Competing Players - Abbott Laboratories - Key Company Facts
Table 9: Competing Players - Eli Lilly and Company - Key Company Facts
Table 10: Competing Players - Novo Nordisk A/S - Key Company Facts
Table 11: Competing Players - Takeda Pharmaceutical Company Limited - Key Company Facts
Table 12: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Company Facts